United Therapeutics Corporation $UTHR Stock Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 33.4% during the third quarter, Holdings Channel.com reports. The firm owned 11,736 shares of the biotechnology company’s stock after selling 5,898 shares during the quarter. Nisa Investment Advisors LLC’s holdings in United Therapeutics were worth $6,360,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $2,868,735,000. Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $450,140,000. Swedbank AB grew its stake in shares of United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after buying an additional 2,350 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of United Therapeutics by 0.8% in the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock valued at $183,306,000 after buying an additional 2,383 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.5%

Shares of NASDAQ:UTHR opened at $587.50 on Friday. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35. The company’s 50 day moving average price is $519.14 and its two-hundred day moving average price is $540.06. The firm has a market cap of $25.20 billion, a PE ratio of 21.02, a PEG ratio of 4.24 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm posted $6.41 EPS. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 26.07 EPS for the current year.

United Therapeutics declared that its board has approved a share repurchase program on Thursday, October 22nd that allows the company to repurchase $2.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $167,432,054.58. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 401,528 shares of company stock valued at $208,338,661 over the last quarter. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on UTHR shares. The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research note on Thursday, October 15th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $708.00 to $697.00 and set an “outperform” rating on the stock in a report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 target price on shares of United Therapeutics in a report on Wednesday, October 14th. Leerink Partners raised their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Finally, Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $650.43.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: $2 billion buyback authorization: United Therapeutics’ board approved an additional $2 billion share-repurchase program, potentially covering up to 8.3% of outstanding shares. The authorization could reduce the share count, support future earnings per share and signal that management considers the stock undervalued. United Therapeutics Authorizes Additional $2 Billion Share Buyback Program
• Positive Sentiment: Analyst targets remain above the current share price: Recent research includes bullish ratings and targets as high as $725. The broader analyst consensus remains “Moderate Buy,” with an average target of approximately $650, although ratings are not unanimous. Analysts Conflicted on United Therapeutics
• Neutral Sentiment: CEO sold a relatively small portion of holdings: CEO Martine Rothblatt sold 9,500 shares for about $5.3 million, reducing her direct ownership by 2.84%. She still owns more than 324,000 shares, so the transaction may represent personal diversification rather than a change in business outlook. SEC Insider Trading Filing
• Negative Sentiment: Tyvaso faces near-term pressure: RBC warned that United Therapeutics’ settlement with Liquidia could weigh on the outlook for Tyvaso, raising concerns about competition and growth for the company’s key pulmonary arterial hypertension franchise. United Therapeutics Tyvaso Outlook Faces Near-Term Pressure

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.